Immunotherapy drug may keep high-risk head and neck cancer at bay
NCT ID NCT02841748
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 28 times
Summary
This study tested whether giving the immunotherapy drug pembrolizumab for one year after standard treatment could delay cancer recurrence in 100 patients with high-risk head and neck cancer. Half received pembrolizumab and half received a placebo. The main goal was to see how long patients lived without their cancer progressing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emory University Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.